1	An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results
2	of an interim analysis of a phase III, parallel group, randomized, double-
3	blind, active-controlled study
4	Julio Torales ^a , Osmar Cuenca-Torres ^a , Laurentino Barrios ^a , Luis Armoa- Garcia ^a , Gladys
5	Estigarribia ^a , Gabriela Sanabria ^a , Meei-Yun Lin ^b , Josue Antonio Estrada ^b , Lila Estephan ^b , Hao-
6	Yuan Cheng ^b , Charles Chen ^b , Robert Janssen ^c , Chia-En Lien ^{b,d*}
7	
8	^a School of Medical Sciences, National University of Asunción, San Lorenzo, Paraguay
9	^b Medigen Vaccine Biologics Corporation, Taipei, Taiwan
10	^c Dynavax Technologies Corporation, Emeryville, CA, USA
11	^d Institute of Public Health, National Yang-Ming Chiao Tung University, Taipei, Taiwan
12	
13	*Corresponding author : Chia-En Lien, MD, DrPH. email: allenlien@medigenvac.com
14	Tel.: +886-2-7745-0830, Address: 7F., No. 16, Ln. 120, Sec.1, Neihu Rd., Taipei City 114, Taiwan.

1 Abstract

Background: Data from previous studies of the MVC-COV1901 vaccine, a subunit vaccine
against SARS-CoV-2 based on the stable prefusion spike protein (S-2P) adjuvanted with CpG
1018 adjuvant and aluminum hydroxide, suggest that the vaccine is generally safe and elicits a
good immune response in healthy adults and adolescents. By comparing with AZD1222, this
study adds to the findings from previous trials and further evaluates the breadth of protection
offered by MVC-COV1901.

Methods : In this phase 3, parallel group, randomized, double-blind, active-controlled trial
conducted in 2 sites in Paraguay, we assigned adults aged 18 to 91 years in a 1:1 ratio to receive
intramuscular doses of MVC-COV1901 or AZD1222 administered as scheduled in the clinical
trial. Serum samples were collected on the day of vaccination and 14 days after the second dose.
Primary and secondary safety and immunogenicity endpoints were assessed. In addition, other
outcomes investigated were cross-reactive immunity against the Omicron strain and the
induction of IgG subclasses.

Results : A total of 1,030 participants underwent randomization. Safety data was derived from this set while primary immunogenicity data involved a per-protocol immunogenicity (PPI) subset including 225 participants. Among the participants, 58% are seropositive at baseline. When compared against AZD1222, MVC-COV1901 exhibited superiority in terms of neutralizing antibody titers and non-inferiority in terms of seroconversion rates. Reactogenicity was generally mild and no serious adverse event was attributable to MVC-COV1901. Both vaccines have a Th1-biased response predominated by the production of IgG1 and IgG3 subclasses. Omicron-

- 22 neutralizing titers were 44.5 times lower compared to wildtype-neutralizing titers among
- 23 seronegative individuals at baseline. This fold-reduction was 3.0 times among the seropositive.
- 24 **Conclusion:** Results presented here demonstrate the safe and robust immunogenicity from
- 25 MVC-COV1901. Previous infection coupled with vaccination of this vaccine may offer
- 26 protection against the Omicron strain though its durability is still unknown.
- 27 Keywords: COVID-19; SARS-CoV-2 vaccine; MVC-COV1901; phase 3 trial; Omicron strain;
- 28 subunit vaccine
- 29 ClinicalTrials.gov registration: NCT05011526

1 Introduction

2 Since it was first reported in December 2019, COVID-19 has rapidly spread affecting 3 millions of lives and causing over 6 million deaths worldwide [1]. High transmission rates have 4 threatened and quickly overwhelmed health systems. The urgency of addressing this pandemic has led to the accelerated development of vaccines from various platforms. To date, over 63.4% 5 6 of the world's population has received at least one dose of a COVID-19 vaccine but the 7 inequitable distribution of vaccine remains a problem. It is estimated that only 13.6% of people in low-income countries have received at least one dose of an approved COVID-19 vaccine [1]. 8 9 Further increasing vaccine coverage and improving vaccine equity require surpassing logistical and supply constraints and the use of vaccines that are proven safe and effective and offer 10 breadth in terms of protection 11

During late 2020, reports from different countries confirmed the emergence of SARS-12 CoV-2 variants that caused differing degrees of transmission, ability to cause severe disease and 13 immune evasion [2]. In November 2021, the first case of the Omicron variant was reported in 14 South Africa [3]. Although found to have a lesser risk for severe disease than the previously 15 16 discovered Delta variant, mutations in the Omicron equipped the variant with greater transmissibility, effectivity in avoiding the human immune response and resistance against some 17 existing treatments [4,5]. By the end of March 2022, more than 90% of SARS-CoV-2 infections 18 19 worldwide were caused by this variant [1]. For populations receiving insufficient protection, an epidemic of the virus may lead to detrimental effects. Although the incidence of severe disease is 20 21 lower, higher transmission leading to a large volume of cases, could overwhelm health systems 22 and threaten economies. As aforementioned, it is crucial that we find solutions that are safe and effective and offer protection against the different variants of the virus. 23

24	MVC-COV1901 is a subunit vaccine based on the stable prefusion spike protein (S-2P)
25	of SARS-Cov-2 adjuvanted with CpG 1018 adjuvant and aluminum hydroxide and has been
26	approved for use in 3 countries [6,7]. A large phase 2 clinical trial has demonstrated its favorable
27	safety and immunogenicity profiles [8]. An immunobridging assessment demonstrated non-
28	inferiority in terms of immunogenicity to AZD1222 with a geometric mean titer (GMT) of
29	neutralizing antibodies equivalent to 3.8 times that of AZD1222. [9]. In terms of safety, the V-
30	Watch program, launched by the Taiwan Centers for Disease Control to monitor post-marketing
31	safety, reported no serious adverse effects for MVC in 2 million doses administered [10]. Among
32	adolescents, the vaccine was well tolerated and had an immunogenic effect that is non-inferior to
33	that of young adults [11]. For stability, this vaccine can be transported and stored in standard
34	refrigeration temperatures and can, therefore, be easily utilized in low-resource settings [12].
35	Here, we report an interim analysis of a phase 3 trial to assess the safety, tolerability, and
36	immunogenicity of two doses of the MVC-COV1901 compared with AZD1222. We assessed
37	the superiority of MVC-COV1901 against AZD1222 in terms of neutralizing antibodies and its
38	non-inferiority in terms of seroconversion. We also looked at other dimensions of immunity
39	particularly the profile of IgG subclass antibody responses among vaccinated individuals. As a
40	huge majority of the infections globally are caused by the Omicron variant, it is imperative that
41	we investigate the immunogenicity of the vaccine against Omicron. This ongoing trial, which
42	began in October 2021, was conducted at the time the Omicron variant was widely circulating.
43	We, therefore evaluated the immune response induced by two doses of the vaccine against the
44	Omicron (BA.1) strain in both the seropositive and seronegative subsamples at baseline.
45	Seropositive individuals considered in this analysis were those with possible prior infection of

46 COVID-19 as indicated by a reactive anti-N protein test and pre-vaccination anti-spike antibody47 titers that are above the lower limit of detection.

48

49 Methods

50 *Study design and participants*

The MVC-COV1901 phase 3 trial was a parallel-group, prospective, randomized, double-51 blind, active-controlled, and multi-center study to evaluate the safety, tolerability, and 52 immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901 compared to AZD1222 53 54 in adult volunteers of 18 years and above (NCT05011526). Figure 1 outlines the trial profile and study schematic. The main study of the trial consisted of 1,030 subjects ≥ 18 years of age who 55 were generally healthy or with stable pre-existing medical conditions recruited from two study 56 sites - Asuncion and Ciudad del Este- in Paraguay. A full list of inclusion and exclusion criteria 57 58 can be found in the appendix. This sample of 1,030 individuals was used for safety analysis. From this sample, the immunogenicity subset which consisted of 884 subjects, was derived. The 59 per-protocol immunogenicity (PPI) analysis set included 225 participants. 60

The trial protocol and informed consent form were approved by the local regulatory
entity (DINAVISA) and the ethics committees at the participating sites. The main institutional
review board was the National University of Asuncion. The phase 3 trial was done in accordance
with the principles of the Declaration of Helsinki.

65 *Randomization and blinding*

66	Eligible participants were unvaccinated individuals randomized to receive either MVC-
67	COV1901 or AZD1222 in a 1:1 ratio. All participants were randomly assigned to study
68	intervention using an interactive web response system (IWRS). Simple random sampling was
69	used to select study participants by study site.
70	Double-blinding was employed in the study; hence, both participants and investigators

were blinded to the participants' assignment of the study intervention. In case of emergency, the

72 investigator held the sole responsibility of determining if unblinding of intervention assignment

rais warranted. Once Day 43 (or 14 days after the second dose) was reached, the interim analysis

vas carried out. Participants, investigators, site personnel, local regulators, and the sponsor staff

were then unblinded to the treatment group assignments.

76 *Procedures*

75

Subjects received two doses of either MVC-COV1901 or AZD1222 as scheduled in the
clinical trial. Both vaccines were delivered intramuscularly at the deltoid. Serum samples were
collected on the day of vaccination (Day 1) and 14 days after the second dose (Day 43 after the
first dose).

The Medigen COVID-19 vaccine, MVC-COV1901, is a subunit vaccine consisting of the
prefusion spike protein (S-2P), 750 µg CpG 1018 adjuvant and 375 µg aluminum hydroxide. A
standard 0.5 mL dose contains 15 µg of the Spike-2P. The active control is AZD1222, an
adenoviral vector vaccine developed by Oxford University and AstraZeneca served in multi-dose
vials. Each dose of vaccine is 0.5 mL and contains 5 × 10¹⁰ viral particles.
For safety analysis, vital signs were checked before and after each injection. Individuals

87 injected with the intervention were observed for at least 30 minutes after administration of the

intervention. This period is for the assessment of immediate adverse events. Participants who 88 received at least one dose of the study intervention were evaluated for safety. Data from these 89 were reported as part of the safety set. Participants were then asked to record any local or 90 systemic adverse events for up to 7 days after each injection. Unsolicited adverse events were 91 reported for 28 days after each dose of the vaccines. Other adverse events, serious adverse 92 93 events, adverse events of special interest, and vaccine-associated enhanced diseases were noted throughout the study period. Levels of the severity of solicited and unsolicited adverse events 94 95 were reported using modified grading scales from the US FDA Guidance for Industry [13]. The levels of severity were not noted for the reporting of "diarrhea" and "nausea" under solicited 96 systemic AEs. 97

For immunogenicity analysis, assessments were conducted on Day 1 and Day 43. 98 Measurement of neutralizing antibody titers was performed by central laboratories in Taiwan 99 100 using validated live virus neutralization assay while determination of antigen-specific 101 immunoglobulin (IgG) titers was performed by a laboratory in Taiwan using validated enzymelinked immunosorbent assay (ELISA) [8]. In brief terms, the live virus neutralization assay was 102 conducted by mixing serially-two-fold diluted sera with an equal volume of SARS-CoV-2 virus 103 104 (hCoV-19/Taiwan/4/2020, GISAID accession ID: EPI_ISL_411927). This serum-virus mixture was incubated and added to Vero E6 cells before further incubation. Neutralizing antibody titer 105 106 (NT_{50}) was defined as the reciprocal of the highest dilution capable of inhibiting 50% of the 107 cytopathic effect. The NT₅₀ results were calculated with the Reed-Muench method. For antigenspecific immunoglobulin titers, serum samples were analyzed in Taiwan using the ELISA 108 method with plates coated with S-2P proteins. GMTs obtained through the assays were converted 109 to standardized units: IU/mL for neutralizing antibody titers and BAU/mL for antigen-specific 110

111	immunoglobulin. For neutralizing antibodies, titers were converted using the equation: y =
112	1.5001($x^{0.8745}$); where x is the value of the GMT. For the IgG titers, titers tested in Taiwan were
113	converted to BAU/mL by multiplying by a conversion factor of 0.0912[8]. For local analysis and
114	usage, IgG titers were also tested in a laboratory in Paraguay. Antigen-specific immunoglobulin
115	titers were tested using the LIAISON® SARS-CoV-2 TrimericS IgG assay, a chemiluminescence
116	immunoassay (CLIA) used for the quantitative determination of anti-trimeric spike protein-
117	specific IgG antibodies to SARS-CoV-2 in serum or plasma samples [14].
118	For the evaluation of the Omicron-neutralizing ability, neutralizing assays using
119	pseudovirus with spike proteins of Wuhan wild-type or the Omicron variant were performed as
120	in the previous study [12]. Twofold serial dilutions of serum samples were mixed with equal
121	volumes of pseudovirus and incubated before adding to the HEK293-hAce2 cells. Fifty percent
122	dilution titers (ID50) were calculated considering the uninfected cells as 100% neutralization and
123	cells transduced with the virus as 0% neutralization.
124	Outcomes
125	The outcomes evaluated in this study were safety, tolerability, and immunogenicity. The
126	primary safety outcomes involved the evaluation of the safety and tolerability of MVC-
127	COV1901 versus AZD1222. Primary safety endpoints include immediate adverse events,
128	solicited local and systemic adverse events (evaluated up to 7 days after each dose of the study
129	intervention), and unsolicited adverse events (assessed up to 28 days after each dose of the study
130	intervention). The primary immunogenicity outcomes, on the other hand, were measured in wild-
131	type anti-SARS-CoV-2 virus-neutralizing antibody GMTs, GMT ratio between MVC-COV1901
132	and AZD1222, geometric mean fold rise (GMFR) from baseline antibody levels, and
133	seroconversion rates (SCR) at day 14 after the second dose of the vaccine. Seroconversion is

134	defined as at least a 4-fold increase of post-intervention antibody titers from the baseline titers or
135	half of the lower limit of detection (LoD), if undetectable, at baseline. The study aims to
136	determine superiority in neutralizing antibodies and non-inferiority in terms of SCR of MVC-
137	COV1901 against AZD1222 measured 14 days after the second dose of the study intervention.
138	Superiority is established when the lower limit of the 95% confidence interval (CI) of the GMT
139	ratio (MVC-COV1901/AZD1222) is greater than 1, while non-inferiority in SCR is considered
140	when the lower limit of the 95% CI of the difference in SCRs (MVC-COV1901/AZD1222) is
141	greater than or equal to -5%.
142	Secondary safety outcomes assessed included serious adverse events, adverse events of
143	special interest, and vaccine-associated enhanced diseases, while the secondary immunogenicity
144	outcome considered was the level of antigen-specific immunoglobulin or IgG (in BAU/mL)
145	measured at Day 43 (i.e. 14 days after the second dose).
146	This study also investigated other dimensions of immunity induced by the primary
147	regimen of the MVC-COV1901. The other outcomes being investigated were cross-reactive
148	immunity against the Omicron strain of SARS-CoV-2 and non-neutralizing antibody immune
149	effector mechanisms particularly the induction of IgG subclasses.
150	Statistical analysis
151	The primary safety outcomes in this interim analysis were assessed in the safety set,
152	which, as previously mentioned, included randomly assigned participants who had at least one
153	dose of study intervention. Primary immunogenicity endpoints were evaluated using the PPI
154	subset consisting of participants who had received two doses of the study intervention, had valid
155	immunogenicity data on Day 43, and had no major protocol deviations up to Day 43.

156	We calculated the sample size based on the following assumptions: (1) Level of
157	significance = 0.025 (one-sided), (2) Level of power = 0.9 , (3) Expected geometric mean ratio of
158	MVC-COV1901 to AZD1222 = 1.2 and (4) SD of natural log data = 0.81 [8]. Under the above
159	assumptions, a sample of 417 participants per group provides a power of 90% to establish
160	superiority of MVC-COV1901 to AZD1222 in terms of GMT ratio of neutralizing antibody titers
161	at day 43. Furthermore, we considered a dropout rate of 11.4% resulting to a total of at least 942
162	participants considered for the study.

All measured variables and derived parameters were listed by individual participant and 163 164 analyzed using descriptive statistics. Summary descriptive statistics were provided for demographic/baseline characteristics, secondary immunogenicity, safety, exploratory 165 166 immunogenicity, and efficacy variables. Continuous variables were summarized descriptively 167 with the number of participants, mean, median, standard deviation (SD), interquartile range (IQR), range (minimum and maximum), and 95% CI of mean and median (when appropriate). 168 Categorical variables were summarized with the number and percentage of participants. The 169 170 geometric means of IgG and neutralizing antibody titers were calculated together with their 95% 171 CIs, whereas GMT ratios, and their 95% CIs were obtained from the ratio of the GMTs of MVC 172 and AZ. Significance tests (2-tailed, alpha = 0.05) without alpha adjustment were performed for pairwise comparison where appropriate and p-value was rounded to four decimal places as 173 174 applicable.

175

176 **Results**

177 Demographics and baseline characteristics

178	Table 1 shows the demographic profile and baseline characteristics of the participants.
179	We found that both groups are comparable across all baseline characteristics. There are no
180	statistically significant differences between the two vaccine groups when considering the
181	different demographic variables (p>0.05). In terms of age, both groups are similar with a mean
182	age of 32.1 years for the MVC-COV1901 group and 32.2 years for the AZD1222 group
183	(p=0.8929). Both groups are predominantly Latino or Hispanic and are primarily males. As in
184	age, BMI of participants were also similar for the two groups (p=0.4318). Lastly, there are more
185	individuals without any comorbidity in both groups.
186	Safety outcomes

The occurrence of adverse events is summarized in Figure 2 (Table S1-1 and S1-2). 187 188 Overall, a total of 465 (45.1%) participants reported solicited local AEs after any dose of the study intervention: 342 (33.2%) participants after the first dose of study intervention and 239 189 190 (25.8%) participants after the second dose of study intervention. The proportion of participants 191 who reported solicited local adverse events after first and second doses of the study intervention was slightly higher in the AZD1222 group than in the MVC-COV1901 group. Majority of these 192 193 participants reported Grade 1 (mild) and some reported Grade 2 (moderate) solicited local adverse events after any dose of study intervention. Pain or tenderness and injection site pruritus 194 195 was the most frequently reported solicited local AE. Grade 3 adverse events were reported for 196 pain or tenderness, injection site pruritus, and hematoma.

A total of 552 (53.6%) participants reported solicited systemic adverse events after any
dose of the study intervention: 480 (46.6%) participants after the first dose of study intervention
and 222 (24.0%) participants after the second dose of study intervention. The proportion of
participants who reported solicited systemic adverse events after any dose of the study

201	intervention was slightly higher in the AZD1222 group than in the MVC-COV1901 group,
202	specifically after the first dose of the study intervention. Most of these participants reported
203	Grade 1 (mild) and a minority reported Grade 2 (moderate) solicited systemic adverse events.
204	The most common solicited systemic adverse events are headache and myalgia. Grade 3 (severe)
205	headaches were reported in the MVC-COV1901 group while a single case of Grade 4 myalgia
206	was reported in the same group. For malaise or fatigue, 2 participants reported Grade 3 incidents
207	after the second dose of MVC. Other reports of Grade 3 solicited systemic adverse events were
208	made for fever, chills and joint pain.
209	A total of 16 (1.6%) participants reported unsolicited adverse events. The most frequently
210	reported of these were gastrointestinal disorders (0.2%) and hypertension (0.2%) . No unsolicited
211	adverse events of at least Grade 3 were deemed related to study intervention. There were 3
212	(0.3%) serious adverse events reported; $2(0.4%)$ of which were from the MVC-COV1901 group
213	while 1 (0.2%) came from the AZD1222 group; however, none of these were related to the study
214	
214	intervention. These SAEs included celiac disease, spontaneous abortion, and COVID-19. No
214	intervention. These SAEs included celiac disease, spontaneous abortion, and COVID-19. No death, VAED, and AE leading to study withdrawal was reported at the time the interim

217 Immunogenicity outcomes

Figure 3 illustrates the rise in neutralizing antibody levels 14 days after the 2nd dose of the

study intervention. Among the seropositive in the PPI subset the wild-type SARS-CoV-2

220 neutralizing antibody GMT were 1905.6 IU/mL (95% CI 1617.98-2244.3) and 1143.4 IU/mL

221 (95% CI 895.3-1460.2) for the MVC-COV1901 and AZD1222 groups, respectively. The GMFR

from baseline were 26.0 (95% CI 19.5-34.7) and 15.0 times (95% CI 10.6-21.1) for MVC-

223 COV1901 and AZD1222 groups, respectively. In the seropositive group, the GMT ratio between

224	MVC-COV1901 and AZD1222 groups was 1.7 (95% CI 1.2-2.2). For the seronegative group,
225	GMT of the MVC-COV1901 group was 434.6 IU/mL (95% CI 333.4-566.5), while that of the
226	AZD1222 group 90.4 IU/mL (95% CI 61.1-133.9). GMFR was higher in this subsample
227	compared to that of the seropositive group with a value of 86.2 times (95 CI% 66.4-111.9) for
228	the MVC and 17.9 times (95% CI 12.2-26.4) for the AZD1222 groups. The GMT ratio between
229	groups was also higher among the seronegative with the MVC-COV1901 group having a
230	neutralizing GMT 4.8 time (95% CI 3.0-7.7) that of the AZD1222 group.
221	Table 2 shows the seroconversion based on the wild-type SARS-CoV-2 neutralizing
231	Table 2 shows the seroconversion based on the wild-type SARS-CoV-2 neutralizing
231 232	Table 2 shows the seroconversion based on the wild-type SARS-CoV-2 neutralizing antibody GMTs. When considering the seronegative participants, the SCR, did not differ
232	antibody GMTs. When considering the seronegative participants, the SCR, did not differ
232 233	antibody GMTs. When considering the seronegative participants, the SCR, did not differ significantly between vaccine groups (p=0.218). The MVC-COV1901 group had a higher SCR,
232 233 234	antibody GMTs. When considering the seronegative participants, the SCR, did not differ significantly between vaccine groups (p=0.218). The MVC-COV1901 group had a higher SCR, with only 1 participant without seroconversion. Among the seropositive, SCRs of both groups
232 233 234 235	antibody GMTs. When considering the seronegative participants, the SCR, did not differ significantly between vaccine groups (p=0.218). The MVC-COV1901 group had a higher SCR, with only 1 participant without seroconversion. Among the seropositive, SCRs of both groups were significantly different (p=0.03). MVC-COV1901 had an SCR of 98.6 % (95% CI 95.9-

Table 3 shows the IgG titers assessed in Taiwan. As previously mentioned, testing was 238 also done in Paraguay for local analysis and usage. Results from both Taiwan and Paraguay were 239 positively and strongly correlated (Spearman's r=0.80, p<0.0001). Based on data from Taiwan, 240 the IgG GMTs in the seronegative subset of the MVC-COV1901 group increased by 239.4 times 241 242 (95% CI 207.5-276.3) from baseline while that of the AZD1222 group rose by 50.8 times (95% 243 CI 43.2-59.7). In terms of GMT ratio between MVC-COV1901 and AZD1222, results show a 244 GMT ratio of 4.7 times (95% CI 3.8-5.9). GMFR for both groups are less when considering the 245 seropositive subsample of the PPI subset. GMT ratio between MVC-COV1901 and AZD1222 was 1.7 times (95% CI 1.5-1.99) as measured in Taiwan. Table 4 shows that the seroconversion 246

247	rate of antigen-specific immunoglobulin titers was 100% (95% CI 91.8-100) in the seronegative
248	subsample of the MVC-COV1901 group on Day 43 after first dose. This was not significantly
249	different from the seroconversion rate demonstrated by the AZD1222 group. Considering only
250	the seropositive, MVC-COV1901 group had an SCR of 93.2% (95% CI 87.4-98.9) while the
251	AZD1222 group had an SCR of 90.1% (95% CI 83.2-97.1).

Assessment of IgG subclasses reveal that the pattern of IgG response in the vaccination 252 253 of both AZD1222 and MVC-COV1901 is predominantly IgG1 or IgG3 (Figure 4). High levels 254 of IgG1 and IgG3 were induced by both vaccines, with the MVC-COV1901 inducing higher IgG 255 subclasses than the AZD1222. Among the seronegative, IgG subclass GMT ratio of the MVC-COV1901 over AZD1222 was the highest for IgG3. Minimal IgG2 and IgG4 were produced in 256 257 both groups. IgG subset levels 14 days after the second dose are shown in Figure 4. The IgG1 258 GMTs in the seronegative is 764 BAU/mL for the MVC-COV1901 group and 208 BAU/mL for 259 the AZD1222 group. IgG3 GMTs, on the other hand, were 608 BAU/mL and 137 BAU/mL for 260 MVC-COV190 and AZD1222 groups, respectively. The GMT ratio between MVC-COV1901 261 and AZD1222 for IgG1 to IgG4 among the seronegative were 3.7, 1.4, 4.4, and 1.0, respectively. To test the neutralizing ability against the Omicron variant, we have subjected sera collected on 262 Day 1 and Day 43 after the first dose (i.e. Day 14 after the second dose) to pseudovirus 263 264 neutralizing assay against wildtype and the Omicron variant. As shown in Figure 5, pseudovirus 265 neutralizing antibody titers for the wildtype was higher than that of the Omicron variant among the seropositive. The baseline reciprocal inhibition dilution 50 (ID_{50}) GMT for the Omicron 266 267 variant was slightly higher in participants in the MVC-COV1901 group (AZD1222: 13.7 [95% 268 CI 6.4-29.4]; MVC-COV1901: 24.3 [95% CI 8.1-73.0]) but no statistical significance was seen in both vaccine groups (p=0.3661). At Day 14 after the second dose of both vaccines, ID₅₀ GMT 269

270	for the neutralizing antibodies against Omicron pseudovirus was 432.0 (95% CI 76.7-2433.9) for
271	AZD1222 and 832.2 (95% CI 389.4-1778.4) for MVC-COV1901. The MVC-COV1901
272	vaccine's level of neutralizing antibodies for the Omicron pseudovirus showed a 3.0- fold
273	(2549.7/832.2) reduction compared to the GMT of wild-type pseudovirus and was 5.2fold
274	(2232.6/432.0) reduction for AZD1222. Between MVC-COV1901 and AZD1222, the GMT ratio
275	of the neutralizing antibodies for the Omicron pseudovirus at day 14 after the second dose was
276	1.9 (95% CI 0.4-10.1). Among seronegative individuals vaccinated with MVC-COV1901, GMTs
277	of neutralizing antibodies for the Omicron variant, were 44.5 (1323.5/29.7) times less compared
278	to the GMTs against the wildtype pseudovirus. The GMT ratio of MVC-COV1901/AZD1222 at
279	Day 43 for the Omicron variant was 3.0 (95% CI 1.1-8.1).

280

281 Discussion

282 In this phase III, parallel group, double-blind, randomized, active-controlled, two-arm, multi-center study, we evaluated the safety and immunogenicity of the MVC-COV1901 in adults 283 284 against AZ. Initiated in October 2021, this trial met the safety and immunogenicity endpoints as 285 stated in the protocol. Findings demonstrate the superiority of MVC-COV1901 in terms of neutralizing antibody titers and its non-inferiority in terms of resulting seroconversion rates. 286 287 Neutralizing antibody GMT of MVC-COV1901 was as high as 4.8 times that of AZD1222 among the seronegative individuals. Seroconversion rate, on the other hand, was 100% among 288 289 seronegative. In terms of safety. MVC-COV1901 was found to be well tolerated and have fewer safety signals compared with AZD1222 and other COVID-19 vaccines [10, 15-17]. 290

Safety data show that adverse events are less frequent for MVC-COV1901. Reported 291 solicited adverse events were mostly mild or moderate. However, unlike in previous studies 292 293 [8,12], adverse events that are at least Grade 3 were reported for some solicited and local adverse events such as pain or tenderness, injection site pruritus, bruising, myalgia and fever. Despite this 294 MVC-COV1901 has a good reactogenicity profile when compared with other vaccines that 295 296 received an emergency use authorization [10]. A notable finding is the lower incidence of fever 297 in the MVC-COV1901 group (10.4%) than in the AZD1222 group (19.0%). This is however, 298 higher compared to the ones observed in the phase 2 trial conducted in Taiwan [8]. While this 299 differential reporting of adverse events may be due to differences in age and sex composition as well as ethnicity of both populations, it is also worth noting that there are other factors which 300 may be of significance such as differences in other social determinants, differences in experience 301 302 of receiving the vaccine, and differences in the cultural context and health systems setup [18]. 303 Unsolicited adverse events, on the other hand, were recorded on both groups. In the MVC-304 COV1901 group, unsolicited adverse events were reported in only 1.6% of the participants in the safety set – a rate lower compared to the reported solicited adverse events. Serious adverse 305 events were reported by less than 1% of the participants, none of these were related to the study 306 307 intervention. We suspect an underreporting of unsolicited adverse events in this clinical trial, by both participants and staff. 308

The phase 3 trial was conducted in Paraguay amidst the SARS-CoV-2 pandemic. Therefore, approximately 58% of the participants were seropositive at baseline. In the seronegative subset, the GMT of the wild-type neutralizing antibody in the MVC-COV1901 group increased to approximately 86 times (95% CI 66.4-111.9) from baseline. Compared to those in the AZD1222 group, the MVC-COV1901 group had a GMT that was as high as 4.8

314	times (95% CI 3.0-7.7) in the seronegative but in the seropositive subsample GMT ratio was 1.7
315	times (95% CI 1.2-2.2). This fulfills the superiority criterion set by the study (i.e. lower limit of
316	the 95% CI must be greater than 1). In addition to this, seroconversion rates consistent with
317	previous studies demonstrated favorable immunogenicity [8,12]. Most of the participants (99.1%
318	in MVC-COV1901 group and 91.7% in AZD1222 group) in both vaccine groups achieved
319	seroconversion based on wildtype neutralizing antibody on Day 14 after the second dose. Results
320	show that the treatment difference between MVC-COV1901 and AZD1222 (i.e. MVC-COV1901
321	– AZD1222) was 7.4% (95% CI: 3.8 – 10.9), fulfilling the non-inferiority criterion of MVC-
322	COV1901 to AZD1222 in SCR of neutralizing antibody. Subgroup analysis in the seronegative
323	subsample reveal higher GMFRs (MVC: 88.8 [95% CI 68.3-115.3]; AZ: 17.9 [95%CI 12.2-
324	26.4]). The GMT ratio between MVC-COV1901 over AZD1222 was 4.8 times (95% CI 3.0-7.7).
325	The difference in seroconversion rates was approximately 5.1% (95% CI: $-2.1 - 12.4$). These
326	also fulfill the superiority criterion for the neutralizing antibodies and non-inferiority criterion for
327	seroconversion.

328 In another immunobridging study, VLA-2001, an inactivated whole virus vaccine also 329 adjuvanted with alum and CpG 1018 adjuvant, produced a GMT ratio of 1.39 between VLA-330 2001 and AZD1222 [19]. Both MCV-COV1901 and VLA-2001 vaccine demonstrated 331 superiority in neutralizing antibodies according to their set criteria. Existing literature suggest 332 that protein subunit vaccines elicit better neutralizing antibody response compared to inactivated 333 virus vaccines [20]. Protein subunit vaccines are purified and stably locked in the preferred prefusion conformation thus the vaccine is presented as a correctly folded immunogen in pure form, 334 whereas in inactivated vaccines, the purification process may affect the spike conformations 335 [21]. 336

337	Vaccination both by MVC-COV1901 and AZD1222 induced a Th-1 skewed immune
338	response [12,21]. AZD1222 demonstrates a Th1-biased response characterized by antibody
339	production predominantly of IgG1 and IgG3 subclasses [22]. In similar fashion, MVC induced a
340	robust Th-1 biased response predominated by IgG1 and IgG3. Our results illustrate that MVC
341	induced slightly higher IgG1 and IgG3 in the seronegative population.

Levels of binding and neutralizing antibodies can be correlated and used to predict 342 vaccine efficacy [23,24]. Reported antibody titers induced by two doses of MVC-343 344 COV1901 concur with those found in previous studies [8,12] which is estimated to confer 90% 345 vaccine efficacy against the ancestral strain [8,9]. The emergence of the other strains and particularly the Omicron strain, however, has increased ability of the virus to evade immunity, 346 347 rendering two doses of currently available vaccines, largely ineffective in neutralization [25-27]. 348 In this study, we illustrate that among seronegative participants two doses of MVC-COV1901 349 led to Omicron-neutralizing titers that are 44.5 times less than Wildtype-neutralizing titers. In the 350 case of AZD1222, the reduction is more pronounced as neutralizing antibody titers against 351 Omicron was barely detectable. As in most of the currently available vaccines, the primary 352 regimen usually offers insufficient protection to the Omicron variant. Boosters are required to 353 improve protection against it [27,28]. Results of this trial however, provide support to existing literature which suggests that natural immunity from previous infection offer a significant boost 354 to protection offered by vaccination [29,30]. As aforementioned, SARS-CoV-2 was endemic in 355 356 Paraguay at the time the study was conducted; hence, approximately 58% of the participants 357 were seropositive. Because this trial started in October 2021 and because the first cases of 358 Omicron were reported in December 2021 [31], the seropositive participants were probably infected by other SARS-CoV-2 variants. Data from seropositive individuals who got MVC-359

COV1901 shots show a 3.0-fold reduction in wildtype-neutralizing titers compared to Omicron 360 neutralizing-titers viz-a-viz the 44.5-fold reduction in the seronegative. Resulting titers among 361 362 the seropositive were 1.8 times higher in MVC-COV1901-vaccinated individuals compared to those vaccinated with AZD1222. A study by Nordstrom et al. [29] suggests that two-dose hybrid 363 immunity (i.e. immunity from two doses of the vaccine plus a previous infection) was associated 364 365 with 66% lower risk of reinfection than natural immunity alone with no significant attenuation 366 up to 9 months. Two doses of hybrid immunity was also associated with a significantly lower 367 risk of hospitalization than natural immunity. Our results, show that among those who might 368 have been previously infected with SARS-CoV-2, the primary regimen of MVC-COV1901 induces immune response which may be sufficient against the evasive Omicron variant. In 369 370 relation to existing literature, these results raise a question on issues such as the sufficiency of two doses as part of the primary vaccination regimen or the requirement of a third dose among 371 previously infected individuals . It also highlights the idea of whether documents indicating the 372 373 person's immune status should also include a history of infection.

We consider the following limitations of the study: first, the sample size of seronegative participants was relatively small due to high local viral transmission rate in the sites at the time of the study. However, this has added to the relevance of the study in real-world settings. Second, the short duration of follow-up did not allow for the assessment of the durability of immune responses among the seropositive and seronegative participants. Third, the neutralization assay used for the Omicron variant was a pseudovirus assay which may not accurately reflect the neutralizing ability against the Omicron (BA.1) variant.

382 Declaration of Competing Interests

- 383 M.-Y. L., C. E. L., J.A.E., L.E., H.-Y.C., and C.C. are employees of Medigen Vaccine
- Biologics Corporation. R.J. is an employee of Dynavax Technologies Corporation. J.T., O.C.T.,
- 385 L.B., L.A.G., G.E., and G.S. declared no conflict of interest. All authors have reviewed and
- approved of the final version of the manuscript.

387 Acknowledgements

- 388 We thank the Institute of Biomedical Sciences, Academia Sinica and Protech
- 389 Pharmaservices Corporation for performing the assays. For conducting the local analysis in
- 390 Paraguay, we thank Les Science Lab in Coronel Oviedo, Paraguay. We also thank the members
- of Medigen Vaccine Biologics Corp. in assisting manuscript editing and revision.

Funding statement

393 The study was funded by Medigen Vaccine Biologics (study sponsor).

394 Author Contribution

- 395 Concept and design: C. E. L., H.-Y. C., C. C.
- Conducting the clinical trial: J.T., O.C.T., L.B., L.A.G., G.E., G.S.
- 397 Acquisition, interpretation, and analysis of data: , C. E. L., M.-Y. L., H.-Y. C., J.A.E., L.E.
- 398 Drafting of the manuscript: C. E. L., M.-Y. L., J.A.E., L.E., R.J.

1 Tables

Statistic	AZD1222 N=510	MVC-COV1901 N=520	Total N=1030	p-value	
Age (years)		1	1		
Mean (SD)	32.2 (11.70)	32.1 (12.12)	32.1 (11.91)		
Median	29.0 (16.0)	28.0 (16.0)	29.0 (16.0)	0.8929	
Min, Max (Range)	18.0 ~ 71.0 (53)	18.0 ~ 91.0 (73)	18.0 ~ 91.0 (73)		
Gender (n/%)			1		
Male	315 (61.8)	304 (58.5)	619 (60.1)	0.070	
Female	195 (38.2)	216 (41.5)	411 (39.9)	0.279	
Ethnicity (n/%)					
Latino or Hispanic	501 (98.2)	509 (97.9)	1010 (98.1)		
White or Caucasian	8 (1.6)	9 (1.7)	17 (1.7)	1	
Asian	1 (0.2)	2 (0.4)	3 (0.3)		
BMI (kg/m2)			1	1	
Mean (SD)	27.6 (5.90)	27.3 (6.33)	27.5 (6.11)		
Median	26.4 (7.7)	26.2 (7.4)	26.3 (7.6)	0.432	
Min, Max (Range)	17.0 ~ 54.7	14.9 ~ 60.1	14.9 ~ 60.1		
Comorbidity					
without	336 (65.9)	330 (63.5)	666(64.7)		
Any	174 (34.1)	190 (36.5)	364 (35.3)		
Arrhythmia	1 (0.2)	1 (0.2)	2 (0.2)	0.416	
Arterial Hypertension	35 (6.9)	25 (4.8)	60 (5.8)		
Asthma	8 (1.6)	17 (3.3)	25 (3.4)		
Cancer	2 (0.4)	1 (0.2)	3 (0.3)		

2 *Table 1. Demographic profile and baseline characteristics of participants.*

Chronic Obstruction Pulmonary Disease (COPD)	0	4 (0.8)	4 (0.4)	
Diabetes	12 (2.4)	11 (2.1)	23 (2.2)	
History of drug allergy	20 (3.9)	13 (2.5)	33 (3.2)	
Kidney Disease	0	4 (0.8)	4 (0.4)	
Liver disease	1 (0.2)	3 (0.6)	4 (0.4)	
Obesity	106 (20.8)	108 (20.8)	214 (20.8)	

3

4

5 *Table 2. Seroconversion rates based on neutralizing antibody titers*

Seroconversion Seropositive in PPI subset	AZD1222	MVC- COV1901	Treatment Difference ¹ , %	p-value ²
^	70	72		
n		· -		
Seroconversion, n(%)	63 (90)	71 (98.6)	8.6	0.03
95% CI	82.97-97.03	95.9-100	1.1-16.1	
Seronegative in PPI subset				
n	39	44		
Seroconversion, n(%)	37 (94.9)	44 (100.0)	5.1	0.218
95% CI	82.7-99.4	91.95-100	-1.8-12	

6 Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,

7 GMFR= geometric mean fold rise, PPI=per-protocol immunogenicity

8 Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody

9 titers from the baseline titer or from half of the lower limit of detection if undetectable at10 baseline.

11 [1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the

12 asymptotic 95% CI. In the case of small cell count (expected count less than 5), exact 95% CI

13 was applied alternatively.

- 14 [2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count less than
- 15 5), Fisher's exact test was applied alternatively
- 16
- 17
- 18 Table 3. Geometric Mean Titers and Geometric Mean Titer Ratio of the Antigen-Specific
- 19 *Immunoglobulin (in BAU/mL)*

	Va	GMT		
Parameter	AZD1222	MVC-COV1901	ratio; (95% CI)	p-value
Seropositive				
n	294	264		
Baseline				
GMT	57.8	56.8		
95%CI	50.4-66.2	49.7-64.9		
Day 14 after 2nd sho	ot			
GMT	1617.7	2812.9	1.7	< 0.0001
95%CI	1460.9-1791.3	2575.4-3072.2	(1.5-1.99)	
GMFR	28.0	49.5		
95% CI	23.6-33.2	42.2-58.1		
Seronegative				
n	146	180		
Baseline				
GMT	4.6	4.6		
95%CI	4.6-4.6	4.6-4.6		
Day 14 after 2nd shot				
GMT	231.5	1091.8	4.7	< 0.0001
95%CI	6CI 196.7-272.4 945.7-1260.5 (3.8-5.9)		<0.0001	
GMFR	50.8	239.4		
95% CI	43.2-59.7	207.5-276.3		

20 Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,

21 GMFR= geometric mean fold rise

22 Note: [1] GMT ratio was computed as, GMT_{MVC-COV1901}/GMT_{AZD1222}

23 [2] p-value based on two-sample t test or Wilcoxon rank sum test

Statistics	AZD1222	MVC- COV1901	Treatment Difference ¹ , %	p-value ²
Seropositive in PPI Subset				
n	71	73		
Seroconversion, n (%)	64 (90.1)	68 (93.2)	3.0	0.5135
95% CI	(83.2-97.1)	(87.4-98.9)	(-5.9-12.0)	
Seronegative in PPI Subset			• • •	
n	38	43		
Seroconversion, n (%)	38 (100.0)	43 (100.0)	0	1
95% CI	(90.7-100.0)	(91.8-100.0)	(0.0-0.0)	

25 Table 4. Seroconversion rates based on Antigen-Specific Immunoglobulin Titers

Abbreviation: n= no. of participants, CI= confidence interval, GMT= geometric mean titer,

27 GMFR= geometric mean fold rise, PPI=per-protocol immunogenicity

28 Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody

titers from the baseline titer or from half of the lower limit of detection if undetectable atbaseline.

31 [1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the


asymptotic 95% CI. In the case of small cell count (expected count less than 5), exact 95% CI

33 was applied alternatively.

34 [2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count less than

35 5), Fisher's exact test was applied alternatively

1 Figures




2


3 *Figure 1. Trial profile*

4

A. Solicited local adverse events



B. Solicited systemic adverse events



- 6 Figure 2. Solicited local (A) and systemic (B) adverse events occurring within 7 days of the first
- and second doses of MVC-COV1901 or AZD1222. Adverse events were graded as mild 7
- 8 (grade1), moderate (grade 2), severe (grade 3), or disabling (grade 4)
- 9


10

Grade 1

Grade 2


Grade 3


Hematoma



- 12 Figure 3. Neutralizing antibody titer in subjects immunized with two doses of either AZD1222 or
- 13 *MVC-COV1901 among the seropositive subsample (left) and seronegative subset.*
- 14 Serum samples were taken before the first vaccination (V2) and 14 days (V4) after the second
- 15 dose of the study intervention and were analyzed using live SARS-CoV-2 neutralization assay.
- 16 The results are shown as IU/mL with symbols indicating individual IU values and the bars
- 17 *indicating the GMT of each group.*
- 18








20

21 Figure 14. IgG subclass titers for the seronegative subsample. Depicted are geometric mean


22 *titers with 95% confidence intervals for the four subclasses of IgG.*

GMT Ratio, MVC_COV1901/AZD1222 (Omicron): 1.93





24



- 25 Figure 5. Results of pseudovirus neutralizing assay against wildtype and the Omicron variant.
- 26 Serum samples taken on Day 43 after the first dose (14 days after the second dose) from 16
- 27 seropositive and 14 seronegative participants who were randomly selected. The results were
- 28 presented by horizontal bars representing geometric mean titer with error bars for 95%
- 29 *confidence interval values.*

REFERENCES


2	1.	Our world in data. Statistics and research coronavirus pandemic (COVID-19) [cited 2022
3		April 20]. Available from: https://ourworldindata.org/coronavirus.
4	2.	Harvey, W.T., Carabelli, A.M., Jackson, B. et al. SARS-CoV-2 variants, spike mutations
5		and immune escape. Nat Rev Microbiol 19, 409–424 (2021).
6		https://doi.org/10.1038/s41579-021-00573-0
7	3.	Peacock TP, Brown JC, Zhou J, Thakur N, Newman J, Kugathasan R, Sukhova K, Kaforou
8		M, Bailey D, Barclay WS. The SARS-CoV-2 variant, Omicron, shows rapid replication in
9		human primary nasal epithelial cultures and efficiently uses the endosomal route of entry.
10		BioRxiv. 2022 Jan 1:2021-12.
11	4.	Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,
12		Lemoine F, Pere H, Veyer D, Puech J. Considerable escape of SARS-CoV-2 variant
13		Omicron to antibody neutralization. bioRxiv. 2021 Jan 1.
14	5.	Iketani S, Liu L, Guo Y, Liu L, Huang Y, Wang M, Luo Y, Yu J, Yin MT, Sobieszczyk
15		ME, Huang Y. Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages.
16		bioRxiv. 2022 Jan 1.
17	6.	Kuo TY, Lin MY, Coffman RL, Campbell JD, Traquina P, Lin YJ, Liu LT, Cheng J, Wu
18		YC, Wu CC, Tang WH. Development of CpG-adjuvanted stable prefusion SARS-CoV-2
19		spike antigen as a subunit vaccine against COVID-19. Scientific reports. 2020 Nov
20		18;10(1):1-0.
21	7.	COVID 19 Vaccine Tracker [cited 2022 April 20]. Available from:
22		https://covid19.trackvaccines.org/.

23	8.	Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP,
24		Wang NC, Lee YL, Lin YL. Safety and immunogenicity of CpG 1018 and aluminium
25		hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim
26		results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in
27		Taiwan. The Lancet Respiratory Medicine. 2021 Dec 1;9(12):1396-406.
28	9.	Estrada, Josue A., Chien-Yu Cheng, Shin-Yen Ku, Hui-Chun Hu, Hsiu-Wen Yeh, Yi-
29		Chun Lin, Cheng-Pin Chen, Shu-Hsing Cheng, Robert Janssen, and I-Feng Lin. 2022.
30		"An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults
31		Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-
32		COV1901" Vaccines. 2022. 10, no. 5: 655. <u>https://doi.org/10.3390/vaccines10050655</u>
33	10	. Taiwan Centers for Disease Control. V-Watch Bulletin Report 2022 March, 2021 [cited
34		2022 April 20]. Available from:
35		https://www.cdc.gov.tw/File/Get/Xwv8akaYldqmvlSsN3_H5Q.
36	11	. Liu, LTC, Chiu, CH, Chiu NC, Tan BF, Lin CY, Lin MY, Lien CE, Chen C, Huang LM.
37		Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in adolescents in
38		Taiwan: A double-blind, randomized, placebo-controlled phase 2 trial. medRxiv. 2022 Mar
39		15.
40	12	. Hsieh S-M, Liu W-D, Huang Y-S, Lin Y-J, Hsieh E-F, Lian W-C, et al. Safety and
41		immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein
42		Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in
43		healthy adults: A Phase 1, dose-escalation study. eClinicalMedicine. 2021;38.
44	13	. U.S. Food and Drug Administration. Guidance for industry: toxicity grading scale for
45		healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.

46	September 2007. Rockville, MD: Center for Biologics Evaluation and Research. 2007
47	[cited May 2022] Available from https://www.fda.gov/regulatory-information/search-fda-
48	guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-
49	enrolled-preventive-vaccine-clinical.
50	14. LIAISON® SARS-CoV-2 TrimericS IgG assay, A quantitative assay for immune status
51	monitoring with an accurate correlation of neutralizing IgG antibodies: Product manual.
52	[cited June 2022] Available from <u>https://www.diasorin.com/en/immunodiagnostic-</u>
53	solutions/clinical-areas/infectious-diseases/covid-19
54	15. Fan, Yu-Jing, Kwok-Hung Chan, and Ivan FN. Hung. 2021. "Safety and Efficacy of
55	COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at
56	Phase 3. Vaccines. 2021, 9(9): 989.
57	16. Rosenblum HG, Gee J, Liu R, Marquez PL, Zhang B, Strid P, et al. Safety of mRNA
58	vaccines administered during the initial 6 months of the US COVID-19 vaccination
59	programme: an observational study of reports to the Vaccine Adverse Event Reporting
60	System and v-safe. The Lancet Infectious Diseases. 2022, 22(6); 802 – 812
61	17. Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, et
62	al. Safety of COVID-19 vaccines. J Med Virol. 2021;93(12):6588-94
63	18. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and
64	Adverse Effects Following Vaccination. JAMA Netw Open. 2021; 4(12) :e2140364
65	19. Valneva. Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-
66	19 Vaccine Candidate VLA2001: Press Release. 2021 [cited May 2022] Retrieved from
67	https://valneva.com/press-release/valneva-reports-positive-phase-3-results-for-
68	inactivated-adjuvanted-covid-19-vaccine-candidate-vla2001/


69	20. McDonald, I., Murray, S.M., Reynolds, C.J. et al. Comparative systematic review and
70	meta-analysis of reac-togenicity, immunogenicity and efficacy of vaccines against SARS-
71	CoV-2. npj Vaccines 6, 74 (2021). https://doi.org/10.1038/s41541-021-00336-1
72	21. Heinz, F.X., Stiasny, K. Distinguishing features of current COVID-19 vaccines: knowns
73	and unknowns of antigen presentation and modes of action. npj Vaccines 6, 104 (2021).
74	https://doi.org/10.1038/s41541-021-00369-6
75	22. Ewer, K.J., Barrett, J.R., Belij-Rammerstorfer, S. et al. T cell and antibody responses
76	induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2
77	clinical trial. Nat Med 27, 270–278 (2021). https://doi.org/10.1038/s41591-020-01194-5
78	23. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune
79	Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.
80	2021.
81	24. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
82	against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine.
83	2021;27(11):2032-40.
84	25. Pérez-Then, E., Lucas, C., Monteiro, V.S. et al. Neutralizing antibodies against the
85	SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus
86	BNT162b2 booster vaccination. Nat Med. 2022. 28, 481-485.
87	26. Gruell, H., Vanshylla, K., Tober-Lau, P. et al. mRNA booster immunization elicits potent
88	neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med.2022. 28,
89	477–480

- 90 27. Singanallur NB, van Vuren PJ, McAuley AJ, Bruce MP, Kuiper MJ, et al. At Least Three
- 91 Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron
- 92 Variant. Front Immunol. 2022. 13:883612
- 93 28. Shen, X. Boosting immunity to Omicron. Nat Med. 2022. 28, 445–446
- 94 https://doi.org/10.1038/s41591-022-01727-0
- 95 29. Nordström, Peter et al. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation
- 96 in individuals with natural and hybrid immunity: a retrospective, total population cohort
- 97 study in Sweden. The Lancet Infectious Diseases. 2022. 22(6); 781 790
- 98 30. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al.
- 99 Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N
- 100 Engl J Med. 2022. 386: 1532-1546
- 101 31. Reuters. Paraguay confirms first cases of Omicron variant of coronavirus. 28 December
- 102 2021. [cited June 2022] Retrieved from
- 103 https://www.reuters.com/world/americas/paraguay-confirms-first-cases-omicron-variant-
- 104 coronavirus-2021-12-27/



A. Solicited local adverse events

First dose



ADDIDL

B. Solicited systemic adverse events


First dose 100 90 80 70 Participants (%) 60 50 Headache Myalgia Malaise or 40 fatigue 30 Fever 20 10 0 MUCCOVISION MUCCOVISION huccovier Muccoviso1 MUCCOVIDO

A101222

ADDIAL

A101222

Second dose



Second dose

Grade 1

Grade 2

Grade 3


Grade 4

Joint pain

A2D1222 COVISO1


Chills

P10122




Seropositive only

Seronegative only



GMT Ratio, MVC-COV1901/AZD1222: 1.7


GMT Ratio, MVC-COV1901/AZD1222 : 4.8




GMT Ratios (MVC-COV1901/AZD1222): lgG1=3.7; lgG2=1.4: lgG3=4.4; lgG4=1.0



Seronegative only



V4



GMT Ratio, MVC_COV1901/AZD1222 (Omicron): 2.97